sonesitatug vedotin

all catalysts(0)

nothing on the calendar yet

News(7)

• Summit snags $2B investment from AstraZeneca, clearing financial overhang
  The all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights.
  biospace · 5d ago
• AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos
  AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with antibody-drug conjugates (ADCs). The newly minted pa…
  fiercebiotech · 5d ago
• AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
  AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
  biospace · 1mo ago
• AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
  AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
  biospace · 1mo ago
• FDA scientists question Capricor data; Legend CEO steps down
  Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…
  biopharma_dive · 2mo ago
• AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
  AstraZeneca remains "very much on track" to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said durin…
  biospace · 2mo ago
• AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
  AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.
  fiercebiotech · 2mo ago